NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization219.34 mln
Float77.45 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.06
Debt-free
ROE
-119
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
ALX Oncology Holdings Inc. is a US-based clinical-stage company working to develop new cancer treatments. Its main drug candidate, Evorpacept, works by blocking a protein called CD47 and is being tested in combination with other cancer therapies across multiple clinical trials targeting conditions such as gastric cancer, breast cancer, multiple myeloma, and lymphoma. The company has built partnerships with organizations including Jazz Pharmaceuticals, MD Anderson Cancer Center, and Sanofi to advance these programs. Founded in 2015 and based in South San Francisco, California, ALX Oncology also holds a licensing agreement with Stanford University.
